About ADMA Biologics (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ADMA
- CUSIP: N/A
- Web: www.admabiologics.com
- Market Cap: $78.67 million
- Outstanding Shares: 25,793,000
- 50 Day Moving Avg: $3.22
- 200 Day Moving Avg: $3.60
- 52 Week Range: $2.67 - $6.88
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.56
- P/E Growth: 0.00
- Annual Revenue: $12.29 million
- Price / Sales: 6.40
- Book Value: $1.07 per share
- Price / Book: 2.85
- EBITDA: ($17,610,000.00)
- Net Margins: -198.99%
- Return on Equity: -791.24%
- Return on Assets: -63.60%
- Debt-to-Equity Ratio: 0.87%
- Current Ratio: 2.83%
- Quick Ratio: 1.99%
- Average Volume: 35,920 shs.
- Beta: 2.48
- Short Ratio: 0.47
Frequently Asked Questions for ADMA Biologics (NASDAQ:ADMA)
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) released its earnings results on Friday, August, 11th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.29. The firm earned $3.40 million during the quarter, compared to analysts' expectations of $3.52 million. ADMA Biologics had a negative net margin of 198.99% and a negative return on equity of 791.24%. View ADMA Biologics' Earnings History.
When will ADMA Biologics make its next earnings announcement?
Where is ADMA Biologics' stock going? Where will ADMA Biologics' stock price be in 2017?
1 analysts have issued twelve-month price objectives for ADMA Biologics' stock. Their predictions range from $13.00 to $13.00. On average, they anticipate ADMA Biologics' stock price to reach $13.00 in the next year. View Analyst Ratings for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Synthetic Biologics (SYN), Conatus Pharmaceuticals (CNAT), Adverum Biotechnologies (ADVM), Dimension Therapeutics (DMTX), Cempra (CEMP), Verastem (VSTM), XBiotech (XBIT), Cellular Biomedicine Group (CBMG), Immune Design Corp. (IMDZ), Verona Pharma Plc (VRP), ImmuPharma PLC (IMM), Cidara Therapeutics (CDTX), MaxCyte (MXCT), Aldeyra Therapeutics (ALDX), Axsome Therapeutics (AXSM), Synthetic Biologics (SYN), Dicerna Pharmaceuticals (DRNA) and DURECT (DRRX).
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Steven A. Elms, Chairman of the Board
- Adam S. Grossman, President, Chief Executive Officer, Director
- Jerrold B. Grossman D.P.S, Vice Chairman of the Board
- Brian Lenz, Chief Financial Officer
- James Mond M.D., Ph.D., Chief Scientific and Medical Officer
- Bernhard R. M. Ehmer, Director
- Bryant E. Fong, Independent Director
- Dov A. Goldstein M.D., Independent Director
- Lawrence P. Guiheen, Independent Director
- Eric I. Richman, Independent Director
How do I buy ADMA Biologics stock?
Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ADMA Biologics stock can currently be purchased for approximately $3.05.
Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$13.00 (326.23% upside)|Consensus Price Target History for ADMA Biologics (NASDAQ:ADMA)
Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|6/28/2017||Maxim Group||Reiterated Rating||Buy||$13.00||Medium|
|8/1/2016||Raymond James Financial, Inc.||Downgrade||Strong-Buy -> Market Perform||N/A|
Earnings History for ADMA Biologics (NASDAQ:ADMA)Earnings History by Quarter for ADMA Biologics (NASDAQ ADMA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/11/2017||Q2 2017||($0.26)||($0.55)||$3.52 million||$3.40 million||View||N/A|
|5/12/2017||Q1 2017||($0.28)||($0.51)||$3.35 million||$2.63 million||View||N/A|
|11/10/2016||Q3 2016||($0.42)||($0.34)||$2.32 million||$2.94 million||View||N/A|
|8/12/2016||Q2||($0.39)||($0.50)||$2.35 million||$2.27 million||View||N/A|
|5/13/2016||Q1||($0.37)||($0.43)||$2.48 million||$2.12 million||View||N/A|
|11/10/2015||Q315||($0.39)||($0.48)||$1.50 million||$1.85 million||View||N/A|
|8/11/2015||Q215||($0.32)||($0.37)||$1.50 million||$1.30 million||View||N/A|
|5/12/2015||Q115||($0.32)||($0.37)||$1.50 million||$1.50 million||View||N/A|
|3/9/2015||Q4 2014||($0.38)||($0.38)||$1.52 million||$1.41 million||View||N/A|
|11/10/2014||Q3 2014||($0.37)||($0.36)||$1.37 million||View||N/A|
Earnings Estimates for ADMA Biologics (NASDAQ:ADMA)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for ADMA Biologics (NASDAQ:ADMA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ADMA Biologics (NASDAQ:ADMA)
Insider Ownership Percentage: 60.44%Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)
Institutional Ownership Percentage: 34.55%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/3/2016||Adam S Grossman||CEO||Buy||200,000||$6.50||$1,300,000.00|| |
|5/3/2016||Brian Lenz||CFO||Buy||2,500||$6.50||$16,250.00|| |
|5/3/2016||James Mond||CMO||Buy||770||$6.50||$5,005.00|| |
|5/3/2016||Jerrold B Grossman||Director||Buy||45,769||$6.50||$297,498.50|| |
|12/8/2015||Adam S. Grossman||CEO||Buy||500||$9.00||$4,500.00|| |
|12/7/2015||Jerrold B Grossman||Director||Buy||500||$9.01||$4,505.00|| |
|12/2/2015||Adam S Grossman||CEO||Buy||2,250||$9.15||$20,587.50|| |
|12/2/2015||Brian Lenz||CFO||Buy||1,000||$9.15||$9,150.00|| |
|12/2/2015||Jerrold B Grossman||Director||Buy||6,000||$9.16||$54,960.00|| |
|12/1/2015||Adam S Grossman||CEO||Buy||1,800||$9.17||$16,506.00|| |
|11/25/2015||Adam S Grossman||CEO||Buy||1,800||$9.18||$16,524.00|| |
|11/20/2015||Adam S Grossman||CEO||Buy||3,861||$9.21||$35,559.81|| |
|3/19/2015||Adam S Grossman||CEO||Buy||2,000||$8.50||$17,000.00|| |
|3/17/2015||Adam S Grossman||CEO||Buy||5,500||$7.98||$43,890.00|| |
|3/17/2015||Jerrold B Grossman||Director||Buy||500||$8.01||$4,005.00|| |
|3/16/2015||Adam S Grossman||CEO||Buy||8,800||$8.03||$70,664.00|| |
|3/16/2015||James Mond||CMO||Buy||1,250||$8.02||$10,025.00|| |
|3/16/2015||Lawrence P Guiheen||Director||Buy||1,000||$7.96||$7,960.00|| |
|3/13/2015||Eric I Richman||Director||Buy||3,500||$7.88||$27,580.00|| |
|9/12/2014||Adam S Grossman||CEO||Buy||4,300||$9.57||$41,151.00|| |
|8/22/2014||Adam S Grossman||CEO||Buy||1,000||$9.50||$9,500.00|| |
|8/14/2014||Adam S Grossman||CEO||Buy||2,100||$9.77||$20,517.00|| |
|6/18/2014||Adam S Grossman||CEO||Buy||1,875||$9.59||$17,981.25|| |
|5/22/2014||Adam S Grossman||CEO||Buy||4,226||$8.15||$34,441.90|| |
|5/15/2014||Adam S Grossman||CEO||Buy||13,400||$7.50||$100,500.00|| |
|5/14/2014||Brian Lenz||CFO||Buy||1,000||$7.50||$7,500.00|| |
|5/14/2014||James Mond||CMO||Buy||1,315||$7.60||$9,994.00|| |
|12/10/2013||Jerrold B Grossman||Director||Buy||3,650||$7.30||$26,645.00|| |
Headline Trends for ADMA Biologics (NASDAQ:ADMA)
Latest Headlines for ADMA Biologics (NASDAQ:ADMA)
Loading headlines, please wait.
ADMA Biologics (ADMA) Chart for Sunday, October, 22, 2017